{"id":"boostrix-ipv-combination-vaccine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Injection site pain, redness, or swelling"},{"rate":"10-20","effect":"Fever"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-20","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. These antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells against these four pathogens. Upon exposure to the actual pathogens, the primed immune system can rapidly mount a protective response.","oneSentence":"Boostrix-IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:13.539Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults"}]},"trialDetails":[{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04300192","phase":"PHASE4","title":"Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-01-27","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":273},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT03697798","phase":"PHASE4","title":"A Study Exploring Whooping Cough Protection in Children and Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-04-18","conditions":"Pertussis","enrollment":122},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT02858440","phase":"PHASE3","title":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-13","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":235},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT00290342","phase":"PHASE3","title":"Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":458},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Tetanus, Poliomyelitis, Hepatitis B","enrollment":721},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00343421","phase":"PHASE3","title":"Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":588},{"nctId":"NCT00831753","phase":"PHASE3","title":"Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-05","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":263},{"nctId":"NCT00304265","phase":"PHASE4","title":"Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-03","conditions":"Pertussis, Diphtheria, Tetanus","enrollment":215},{"nctId":"NCT00804284","phase":"","title":"Database Surveillance Safety Study of PENTACEL® Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":62538},{"nctId":"NCT01346293","phase":"PHASE3","title":"Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-04","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":3372},{"nctId":"NCT00287092","phase":"PHASE3","title":"Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-02","conditions":"Pertussis, Diphtheria, Tetanus","enrollment":807},{"nctId":"NCT00355654","phase":"PHASE3","title":"Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Infant, Healthy","enrollment":847},{"nctId":"NCT00401531","phase":"PHASE3","title":"Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Hepatitis B, Polio, Diphtheria","enrollment":412},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00255047","phase":"PHASE3","title":"Safety and Immune Response of Different Pediatric Combination Vaccines.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-11","conditions":"Diphtheria, Polio, Pertussis","enrollment":2167},{"nctId":"NCT00294294","phase":"PHASE4","title":"Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-05","conditions":"Vaccines, Pneumococcal, Infant, Fever, Chemically Induced","enrollment":300},{"nctId":"NCT00662870","phase":"PHASE3","title":"Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Diphtheria, Tetanus, Whooping Cough","enrollment":1941},{"nctId":"NCT00355121","phase":"PHASE2","title":"Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Meningococcal Meningitis, Tetanus, Diphtheria","enrollment":882}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Boostrix®-IPV combination vaccine","genericName":"Boostrix®-IPV combination vaccine","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Biologic","firstApprovalDate":"","aiSummary":"Boostrix-IPV is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}